-
1Academic Journal
Authors: O. A. Koneva, O. V. Desinova, L. P. Ananyeva, N. V. Kovaleva, О. А. Конева, О. В. Десинова, Л. П. Ананьева, Н. В. Ковалева
Source: Rheumatology Science and Practice; Vol 56, No 5 (2018); 591-599 ; Научно-практическая ревматология; Vol 56, No 5 (2018); 591-599 ; 1995-4492 ; 1995-4484 ; undefined
Subject Terms: функциональные легочные тесты, interstitial lung disease, multi-slice spiral computed tomography, pulmonary function tests, интерстициальное поражение легких, мультиспиральная компью- терная томография
File Description: application/pdf
Relation: https://rsp.mediar-press.net/rsp/article/view/2623/1757; Varga J, Abraham D. Systemic sclerosis: prototypic multisystem fibrotic disorder. J Clin Invest. 2007;117(3):557-67. doi:10.1172/JCI31139; Wells AU. Interstitial lung disease in systemic sclerosis. Presse Мed. 2014;43:329-43. doi:10.1016/j.lpm.2014.08.002; Capelli S, Bellando Randone S, Camiciottoli G, et al. Interstitial lung disease in systemic sclerosis: where do we stand? Eur Respir Rev. 2015;24(137):411-9. doi:10.1183/16000617.00002915; Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis. 1972–2002. Ann Rheum Dis. 2007;66:940-4. doi:10.1136/ard.2006.066068; Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis. 2010;69(10):1809-15. doi:10.1136/ard.2009.114264; Plastiras SC, Karadimitrakis SP, Ziakas PD, et al. Scleroderma lung: initial forced vital capacity as predictor of pulmonary function decline. Arthritis Rheum. 2006;55(4):598-602.; Fransen J, Popa-Diaconu D, Hesselstrand R, et al. Clinical prediction of 5-year survival in systemic sclerosis: validation of a simple prognostic model in EUSTAR centres. Ann Rheum Dis. 2011;70(10):1788-92. doi:10.1136/ard.2010.144360; Khanna D, Clements PJ, Furst DE, et al. Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: Results from the scleroderma lung study. Arthritis Rheum. 2005;52(2):592-600. doi:10.1002/art.20787; Simeon CP, Armadans L, Fonollosa V, et al. Mortality and prognostic factors in Spanish patients with systemic sclerosis. Rheumatology (Oxford). 2003;42(1):71-5. doi:10.1093/rheumatology/keg033; Wells AU, Hansell DM, Rubens MB, et al. The predictive value of appearances on thin-section computed tomography in fibrosing alveolitis. Am Rev Respir Dis. 1993;148:1076-82. doi:10.1164/ajrccm/148.4_Pt_1.1076; Wells AU, Hansell DM, Corrin B, et al. High resolution computed tomography as a predictor of lung histology in systemic sclerosis. Thorax. 1992;47:738-42. doi:10.1136/thx.47.9.738; Pignone A, Matucci-Cerinic M, Lombardi A, et al. High resolution computed tomography in systemic sclerosis. Real diagnostic utilities in the assessment of pulmonary involvement and comparison with other modalilities of lung investigation. Clin Rheumatol. 1992;11:465-72. doi:10.1007/BF02283100; Sergiacomi G, De Nardo D, Carpia A, et al. Non-invasive diagnostic and functional evaluation of cardiac and pulmonary involvement in systemic sclerosis. In Vivo. 2004;18:229-35.; Chan TY, Hansell DM, Rubens MB, et al. Cryptogenic fibrosing alveolitis and the fibrosing alveolitis of systemic sclerosis: morphological differences on computed tomographic scans. Thorax. 1997;52:265-70. doi:10.1136/thx.52.3.265; Wells AU, Steen V, Valentini G. Pulmonary complications: one of the most challenging complications of systemic sclerosis. Rheumatology (Oxford). 2009;48:40-4. doi:10.1093/rheumatology/kep109; Desai SR, Veeraraghavan S, Hansell DM, et al. CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia. Radiology. 2004;232:560-7. doi:10.1148/radiol.2322031223; Launay D, Remy-Jardin M, Michon-Pasturel U, et al. High resolution computed tomography in fibrosing alveolitis associated with systemic sclerosis. J Rheumatol. 2006;33:1789-801.; Assayag D, Kadury S, Hudson M, et al. High resolution computed tomography scoring systems for evaluating interstitial lung disease in systemic sclerosis patients. Rheumatology. 2012;S1:003. doi:10.4172/2161-1149. S1-003; Walsh SLF, Sverzellati N, Devaraj A, et al. Connective tissue disease related fibrotic lung disease: high resolution computed tomographic and pulmonary function indices as prognostic determinants. Thorax. 2014;69(3):216-22. doi:10.1136/thoraxjnl-2013-203843; Watadani T, Sakai F, Johkoh T, et al. Interobserver variability in the CT assessment of honeycombing in the lungs. Radiology. 2013;266(3):936-44. doi:10.1148/radiol.12112516; Sundaram B, Gross BH, Martinez FJ, et al. Accuracy of high-resolution CT in the diagnosis of diff use lung disease: effect of predominance and distribution of findings. AJR Am J Roentgenol. 2008;191(4):1032-9. doi:10.2214/AJR.07.3177; Daoussis D, Liossis SN, Tsamandas AC, et al. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology. 2010;49:271-80. doi:10.1093/rheumatology/kep093; Tashkin DP, Elashoff R, Clements PG, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354:2655-66. doi:10.1056/NEJMoa055120; Wells AU, Desai SR, Rubens MB, et al. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med. 2003;167(7):962-9. doi:10.1164/rccm.2111053; Kazerooni EA, Martinez FJ, Flint A, et al. Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. AJR Am J Roentgenol. 1997;169(4):977-83. doi:10.2214/ajr.169.4.9308447; Warrick JH, Bhalla M, Schabel SI, Silver RM. High resolution computed tomography in early scleroderma lung disease. J Rheumatol. 1991;18(10):1520-8.; Steen VD, Conte C, Owens GR, Medsgar T. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum. 1994;37:1283-9. doi:10.1002/art.1780370903; Zompatori M, Leone MB, Giannotta M, et al. Pulmonary hypertension and systemic sclerosis: the role of high-resolution computed tomography. Radiol Med. 2013;118:1360-72. doi:10.1007/s11547-013-0934-1; Лесняк ВН, Ананьева ЛП, Конева ОА и др. Полуколичественные визуальные методы оценки выраженности интерстициальных поражений легких по данным компьютерной томографии при системной склеродермии. Пульмонология. 2017;27(1):41-50 [Lesnyak VN, Anan'eva LP, Koneva OA, et al. Semi-quantification image methods for assessing severity of scleroderma-associated interstitial lung; disease according to computed tomography data. Pul’monologiya = Russian Pulmonology. 2017;27(1):41-50 (In Russ.)]. doi:10.18093/0869_0189_2017_27_1_41_50.; Goh NS, Desai SR, Veeraraghavan S, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med. 2008;177(11):1248-54. doi:10.1164/rccm.200706-877OC; Moore O, Goh N, Corte T, et al. Extent of disease on high- resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis – related interstitial lung disease. Rheumatology. 2013;52:155-60. doi:10.1093/rheumatology/kes289; Van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum. 2013;65(11):2737-47. doi:10.1002/art.38098; Fischer A, Swigris JJ, Bolster MB, et al. Pulmonary hypertension and interstitial lung disease within PHAROS: impact of extent of fibrosis and pulmonary physiology on cardiac haemodynamic parameters. Clin Exp Rheumatol 2014;32 Suppl. 86:109-14.; Wells AU, Hansell DM, Rubens MB, et al. Fibrosing alveolitis in systemic sclerosis: indices of lung function in relations to extent of disease on computed tomography. Arthritis Rheum. 1997;40:1229-36.; Davas EM, Peppas C, Maragou M, et al. Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma. Clin Rheumatol. 1999;18(6):455-61. doi:10.1007/s100670050138; White B, Moore WC, Wigley FM, et al. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med. 2000;132(12):947-54. doi:10.7326/0003-4819-132-12-200006200-00004; Vallentini G, Della Rossa A, Bombardier S, et al. European multicentre study of define disease activity variables and development of preliminary activity indexes. Ann Rheum Dis. 2001;60:592-8. doi:10.1136/ard.60.6.592; Nichtyanova SI, Tang EC, Coghlan JG, et al. Improved survival in systemic sclerosis is associated with better ascertainment of internal organ disease: a retrospective cohort study. QJM. 2010;103:109-15. doi:10.1093/qjmed/hcp174; Van Laar JM, Farge D, Sont JK, et al. High dose immunoablation and autolougous hematopoetic stem cell transplantation versus monthly intravenous pulse therapy cyclophosphamide in severe systemic sclerosis [abstract]. Arthritis Rheum. 2012;64:4167.; Ariani A, Silva M, Seletti V, et al. Quantitative chest computed tomography is associated with two prediction models of mortality in interstitial lung disease related to systemic sclerosis. Rheumatology. 2017;56:922-7. doi:10.1093/rheumatology/kew480; Harrison NK, Myers AR, Corrin B, et al. Structural features of interstitial lung disease in systemic sclerosis. Am Rev Respir Dis. 1991;144(3 Pt 1):706-13. doi:10.1164/ajrccm/144.3_Pt_1.706; Lopes AJ, Capone D, Mogami R. Systemic sclerosis-associated interstitial pneumonia: evaluation of pulmonary function over fiveyear period. J Bras Pneumol. 2011 Mar-Apr;37(2):144-51. doi:10.1590/S1806-37132011000200003; De Santis M, Bosello SL, Peluso G, et al. Bronchoalveolar lavage fluid and progression of scleroderma interstitial lung disease. Clin Respir J. 2012 Jan;6(1):9-17. doi:10.1111/j.1752-699X.2010.00228.x; Winstone TA, Assayag D, Wilcox PG, et al. Predictors of mortality and progression in scleroderma-associated interstitial lung disease. Systematic review. Chest. 2014;146(2):422-36. doi:10.1378/chest.13-2626; Khanna D, Brown KK, Klements PJ, et al. Systemic sclerosisassociated interstitial lung diseases – proposed recommendations for future randomized clinical trails. Clin Exp Rheumatol. 2010;28(2 Suppl 58):55-62.; Khanna D, Tseng CH, Farmani N, et al. Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo Group. Arthritis Rheum. 2011 Oct;63(10):3078-85. doi:10.1002/art.30467; Diot E, Giraudeau B, Diot P, et al. Is anti-topoisomerase I a serum marker of pulmonary involvement in systemic sclerosis? Chest. 1999 Sep;116(3):715-20. doi:10.1378/chest.116.3.715; Liu X, Mayes MD, Pedroza C, et al. Does C-reactive protein predict the long-term progression of interstitial lung disease and survival in patients with early systemic sclerosis? Arthritis Care Res (Hoboken). 2013 Aug;65(8):1375-80. doi:10.1002/acr.21968; McQueen FM, Solanki K. Rituximab in diffuse cutaneous systemic sclerosis: should we be using it today? Rheumatology (Oxford). 2015;54(5):757-67. doi:10.1093/rheumatology/keu463; Daoussis D, Liossis SN, Tsamandas AC, et al. Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis. Clin Exp Rheumatol. 2012;30(2 Suppl 71):17-22.; Bosello S, De Santis M, Lama G, et al. B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up openlabel trial. Arthritis Res Ther. 2010;12(2):54. doi:10.1186/ar2965; Smith V, van Praet JT, Vandooren B, et al. Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis. 2010;69(1):193-7. doi:10.1136/ard.2008.095463; Smith V, Piette Y, van Praet JT, et al. Two-year results of an open pilot study of a 2-treatment course with rituximab in patients with early systemic sclerosis with diffuse skin involvement. J Rheumatol. 2013;40(1):52-7. doi:10.3899/jrheum.120778; Jordan S, Distler JH, Maurer B, et al. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis. 2015;74(6):1188-94. doi:10.1136/annrheumdis-2013-204522; Keir GJ, Maher TM, Ming D, et al. Rituximab in severe, treatment-refractory interstitial lung disease. Respirology. 2014;19(3):353-9. doi:10.1111/resp.12214; Ананьева ЛП, Десинова ОВ, Конева ОА и др. Лечение ритуксимабом интерстициального поражения легких при системной склеродермии. Научно-практическая ревматология. 2013;51(5):514-23 [Ananyeva LP, Desinova OV, Koneva OA, et al. Rituximab treatment for interstitial lung injury in scleroderma systematica. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2013;51(5):514-23 (In Russ.)]. doi:10.14412/1995-4484-2013-1542.; Schurawitzki H, Stiglbauer R, Graninger W, et al. Interstitial lung disease in progressive systemic sclerosis: high-resolution CT versus radiography. Radiology. 1990;176:755-9. doi:10.1148/radiology. 176.3.2389033; Remy-Jardin M, Remy J, Wallaert B, et al. Pulmonary involvement in progressive systemic sclerosis: sequential evaluation with CT, pulmonary function tests, and bronchoalveolar lavage. Radiology. 1993;188:499-506. doi:10.1148/radiology. 188.2.8327704; Goldin JG, Lynch DA, Strollo DC, et al. High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease. Chest. 2007;134:358-67. doi:10.1378/chest.07-2444; Овсянникова ОБ. Клинико-инструментальная характеристика интерстициального поражения легких при системной склеродермии: Автореф. дис. … канд. мед. наук. Москва; 2017. С. 10-5 [Ovsyannikova OB. Kliniko-instrumental'-naya kharakteristika interstitsial'nogo porazheniya legkikh pri sistemnoi; sklerodermii [Clinical and instrumental characteristics of interstitial lung lesions in systemic scleroderma]: Author's abstract. dis. . cand. med. science. Moscow; 2017. P. 10-5 (In Russ.)].; Wells AU. High-resolution computed tomography and scleroderma lung disease. Rheumatology. 2008;47 Suppl. 5:59-61. doi:10.1093/rheumatology/ken271; Van der Bruggen-Bogaarts BAHA, Broerse JJ, Lammers JWJ, at al. Radiation exposure in standard and high-resolution chest CT scans. Chest. 1995;107:113-5. doi:10.1378/chest.107.1.113; Brenner DJ, Hall EJ. Computed tomography—an increasing source of radiation exposure. N Engl J Med. 2007;357:2277-84. doi:10.1056/NEJMra072149; Mayo JR. CT evaluation of diffuse infiltrative lung disease: dose considerations and optimal technique. J Thorac Imaging. 2009;24:252-9. doi:10.1097/RTI.0b013e3181c227b2; Behr J, Furst DE. Pulmonary function tests. Rheumatology. 2008;47 Suppl. 5:65-7. doi:10.1093/rheumatology/ken313